Novartis

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products, including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment includes researching, distributing and selling patented pharmaceuticals. The Sandoz segment focuses on marketing finished dosage form medicines and intermediary products including active pharmaceutical ingredients. The Corporate segment is involved in group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Novartis (NVS) throws light on its pipeline progress, key areas of focus and long-term targets at its R&D day. Here, we discuss key highlights from the same.

Novartis (NVS) Highlights Growth Profile at its R&D Day

Merck

As 2021 winds down, investors may want to keep an eye on several drug companies that hope to get key approvals from the Food and Drug Administration before the year is out. Among the pharmas hoping to get their treatments green-lighted are Argenx SE ( ARGX , Financial), Calliditas Therapeutics AB ( CALT , Financial), Merck & Co. Inc. ( MRK , Financial) and Novartis ( NVS , Financial).

Merck, Novartis in Line for Key FDA Approvals This Month

Aurinia Pharmaceuticals

Aurinia Pharma (AUPH) stock is on the rise Thursday as investors hold out hope for a takeover of the company by Novartis (NVS). The post AUPH Stock: The Novartis Takeover Talk That Has Aurinia Pharma Shares Taking Off Today appeared first on InvestorPlace.

AUPH Stock: The Novartis Takeover Talk That Has Aurinia Pharma Shares Taking Off Today

Swiss drugmaker Novartis is confident to reach a core margin in innovative medicines in the high 30s by 2026 and grow sales by 4% each year until the end of that period, the company said in a presentation on Thursday.

Novartis sees annual sales growth of 4% until 2026

Basel, December 2, 2021 — Novartis today holds an investor event to provide a comprehensive overview of the company's progress in advancing its industry-leading R&D engine.

Novartis R&D day spotlights attractive growth profile, underpinned by strong in-market brands, 20 potential high value pipeline assets, and technology platforms

Amgen

AstraZeneca

Bristol-Myers

Horizon Pharma

Vertex Pharmaceuticals

Viatris

Covid-19 stocks soared to unsustainable highs as investors ignored drug stocks with a deep pipeline of products for the decade ahead. The post 7 Drug Stocks to Buy Now While They're Still on Sale appeared first on InvestorPlace.

7 Drug Stocks to Buy Now While They're Still on Sale

Novartis is keeping all options open for the future of its generics division Sandoz, its chairman said in an interview with Swiss TV channel TeleZüri to be broadcast on Tuesday.

Novartis chairman says all options open for Sandoz unit - report

Novartis' stock price does not seem to reflect its increasingly positive fundamentals.

Novartis: Management Should Repurchase The Discounted Stock

Sanofi

U.S. investors often focus on owning domestic companies, as this is the region of the world they are likely most familiar with. As such, this can limit the number of quality stocks available to them for purchase.

A Trio of International Health Care Stocks for Income

Roche Holding AG

Roche shareholders voted overwhelmingly on Friday to support the $20.7 billion deal to buy Novartis's nearly one third voting stake, the Swiss drugmaker said.

Roche shareholders approve deal to buy Novartis's stake

Many stocks are ridiculously expensive right now -- but not these three.

3 Pharma Stocks That Are Too Cheap to Ignore

CVS Health

Patterson Companies

Needless to say, 2021 has been a banner year for equities, with the S&P 500 up a stunning 25%.

Top Strategist Says Health Care Could Rule in 2022: 5 Dividend Winners

According to a German newspaper, Swedish-based investment group EQT and the Struengmann family of Germany are considering a joint move to purchase the Novartis AG's (NYSE: NVS) generics outfit, Sandoz, for $21.6 billion. The price would make it the largest pharma deal of the year.

Novartis May Have Buyer(s) For Its Sandoz Unit - Report

BioNTech SE

Investment group EQT and members of the Struengmann family, who are investors in Biontech, are considering a joint bid for Swiss pharmaceutical group Novartis's generics division Sandoz, German newspaper Handelsblatt reported on Friday, citing unnamed sources.

EQT, Biontech investor family consider Sandoz bid - Handelsblatt

Novartis AG (NYSE: NVS) is getting a massive influx of cash from selling its 20-year stake in Roche Holdings AG (OTC: RHHBY), triggering speculation about where the Company will spend the money.  Another significant acquisition could be next.

Novartis Has $21B From Roche Stake Sale - Which Company Is On Its M&A Radar?

Currently, there are many indicators showing that the U.S. stock market is overvalued.

3 Big Pharma Stocks Trading Near 52-Week Lows

KDDI Corp

Lockheed Martin

Altria

Unilever

High inflation, low-interest rates, and a 30% overvalued S&P create a perfect storm for retirees worried about making ends meet. Fortunately, the world's best high-yield Ultra SWANs can still help you beat inflation, retire rich, stay rich in retirement, and likely let your children and grandchildren retire even richer.

The 5 Safest High-Yield Blue-Chips Retirees Can Buy Today

Johnson & Johnson

Pfizer

S&P 500 investors can expect an average annual return of 7%, with upside potential based on the speed of technological innovation, according to DataTek Research.

Pfizer, J&J and Novartis Capture Top 3 Spots in Innovation Index

Applied Materials

Coinbase

Intel

StoneCo

Patient investors who overcome short-term distractions will get a windfall with these stocks to buy, as they're set to grow at a faster pace. The post 7 Stocks to Buy That Will Make You Rich by 2030 appeared first on InvestorPlace.

7 Stocks to Buy That Will Make You Rich by 2030

Alcon Inc. - Registered Shares

Since being spun off into a separate company in April 2019, Alcon Inc. ( ALC , Financial) shares have thrived while the stock of its former parent, Novartis AG ( NVS , Financial), has languished.

Alcon Big Winner in 2019 Divorce From Novartis

Novartis AG (NYSE: NVS) terminated its ex-US rights to the program dubbed vibecotamab, a bispecific targeting CD123 and CD3 for acute myeloid leukemia.  The move will take effect next February, Xencor Inc (NASDAQ: XNCR) said.

Novartis Dumps Another Bispecific Candidate From Xencor Deal

Atmos Energy

Colgate-Palmolive

Con Ed

Hormel Foods

Kimberly-Clark

Northwest Natural Gas

The market is up 8% in a few weeks, and the 28% overvalued S&P 500 offers near-zero inflation and risk-adjusted expected returns over the next five years. Fortunately, there are always wonderful blue-chips available at reasonable to attractive prices, even high-yield, low-volatility dividend aristocrats.

The 10 Safest High-Yield Dividend Aristocrats To Buy With The Market At Record Highs

Roche's $20.7 billion move to buy back nearly a third of its voting stock from fellow Swiss drugmaker Novartis will give it more strategic flexibility, Chairman Christoph Franz said in an interview published on Saturday.

Roche chairman sees greater flexibility after Novartis deal - paper

Novartis AG (NYSE: NVS) has announced Phase 2 trial data of iptacopan, a selective factor B inhibitor, in patients with C3 glomerulopathy (C3G). In C3G, an overly-active alternative complement pathway causes deposits of C3 protein to build up in blood vessels that filter waste and remove extra fluids from the blood.

Novartis' Iptacopan Meets Primary Endpoint Goal In Rare Kidney Disease Trial

Basel, November 4, 2021 — Novartis will highlight new data on Scemblix® (asciminib), recently approved by the US Food and Drug Administration, as well as its next-generation CAR-T platform and the latest research results for an array of hematology medicines at the 63rd American Society of Hematology (ASH) Annual Meeting & Exposition (December 11-14; Atlanta and virtually). More than 100 abstracts, including 24 oral presentations, will be shared at the meeting.

New data at ASH spotlight Novartis recently approved Scemblix®, next-generation CAR-T platform and expanding hematology portfolio

News for Novartis Stock (NVS)